mTOR inhibitors, PI3K inhibitors, Akt inhibitors, and dual PI3K/mTOR inhibitors have all been studied as monotherapy or in combination with other inhibitors in the treatment and prevention of cancer. This evidence concerns the gene PIK3CA and cancer.